Shots:
- Dewpoint to receive up front payment and up to $239M as research, development & commercial milestones along with royalties on sales of the therapies
- The companies collaborated for the development of therapies to treat DM1
- The companies will collaborate their expertise to advance the novel therapeutic solutions addressing the patients’ needs
Click here to read full press release/ article | Ref: PRNewswire | Image: Business Wire
The post Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy first appeared on PharmaShots.
